Celgene to buy Juno Therapeutics for $9bn
Celgene has signed an agreement to acquire integrated biopharmaceutical firm Juno Therapeutics for around $9bn.
Under the deal, Celgene will purchase Juno’s stock by paying $87 per share in cash.
Juno is engaged in the development of novel cellular immunotherapies for the treatment of cancer.
The company has developed cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to distinguish and kill cancer.
The acquisition will add JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene's lymphoma program. It is a CD19-directed CAR T currently in a pivotal program for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
In the US, JCAR017 is expected to receive approval in 2019.
Read more: http://bit.ly/CelgeneJuno
Under the deal, Celgene will purchase Juno’s stock by paying $87 per share in cash.
Juno is engaged in the development of novel cellular immunotherapies for the treatment of cancer.
The company has developed cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to distinguish and kill cancer.
The acquisition will add JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene's lymphoma program. It is a CD19-directed CAR T currently in a pivotal program for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
In the US, JCAR017 is expected to receive approval in 2019.
Read more: http://bit.ly/CelgeneJuno